Skip to Content
MilliporeSigma

Skip To

1448901

USP

Mupirocin

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S)]]-L-talonon-2-enonic acid 8-carboxyoctyl ester, BRL 4910A, Pseudomonic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
50 mg

Available to ship TODAYfromMILWAUKEE

$455.00

About This Item

Empirical Formula (Hill Notation):
C26H44O9
CAS Number:
Molecular Weight:
500.62
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

$455.00


Available to ship TODAYDetails


Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

pharmaceutical primary standard

agency

USP

API family

mupirocin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[H][C@@]1(CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O)C[C@@H]2O[C@@]2([H])[C@@H](C)[C@H](C)O

InChI

1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1

InChI key

MINDHVHHQZYEEK-HBBNESRFSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Mupirocin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Antibiotic; inhibits isoleucyl-tRNA synthetase (IRS).

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
M7694PHR28061448923
manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

-

manufacturer/tradename

USP

grade

pharmaceutical primary standard

grade

-

grade

pharmaceutical secondary standard

grade

pharmaceutical primary standard

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

pharmaceutical

application(s)

pharmaceutical (small molecule)

format

neat

format

-

format

-

format

neat

API family

mupirocin

API family

-

API family

mupirocin

API family

mupirocin


Still not finding the right product?

Explore all of our products under Mupirocin


Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



M E H Jaspers et al.
Burns : journal of the International Society for Burn Injuries, 40(8), 1570-1574 (2014-04-02)
Staphylococcus aureus wound colonization frequently occurs in patients with burns and can cause impaired wound healing. Nasal mupirocin application may contribute to the reduction of burn wound colonization of endogenous origin, whereas colonization by the exogenous route can be reduced
Kevin B Laupland et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37(7), 933-938 (2003-09-18)
Most Staphylococcus aureus infections are endogenously acquired, and treatment of nasal carriage is one potential strategy for prevention. We critically appraised the published evidence regarding the efficacy of intranasal mupirocin for eradication of S. aureus nasal carriage and for prophylaxis
B D Cookson
The Journal of antimicrobial chemotherapy, 41(1), 11-18 (1998-03-25)
Mupirocin was introduced into clinical practice in the UK in 1985, and has proved to be an extremely effective treatment of skin infections and one of the most successful topical antibiotics for the clearance of nasal Staphylococcus aureus isolates including



Global Trade Item Number

SKUGTIN
1448901-50MG04061833860557

Questions

Reviews

No rating value

Active Filters